GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AGIO · Sep 30, 2025

AGIOS PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001439222-25-000116General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

12.07% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-684.40% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

43.69% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

248.71% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

86.96% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-907.37% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

673.88% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

96.09% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 7.03%
Current: 12.07%
Delta: 5.05%

Cash Generation Decreased

Previous: -619.22%
Current: -684.40%
Delta: -65.18%

Growth Decreased

Previous: 44.57%
Current: 43.69%
Delta: -0.89%

Inventory Pressure Increased

Previous: 247.68%
Current: 248.71%
Delta: 1.04%

Margin Increased

Previous: 86.33%
Current: 86.96%
Delta: 0.63%

Profitability Increased

Previous: -1020.12%
Current: -907.37%
Delta: 112.75%

R And D Intensity Decreased

Previous: 738.18%
Current: 673.88%
Delta: -64.30%

Sbc Intensity Decreased

Previous: 117.96%
Current: 96.09%
Delta: -21.87%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · AGIO Fundamental State →Transitioned To · AGIO Fundamental State →Transitioned To · AGIO CAPEX_INTENSITY_INCREASED →Transitioned To · AGIO CASH_GENERATION_DECREASED →Transitioned To · AGIO GROWTH_DECREASED →Transitioned To · AGIO INVENTORY_PRESSURE_INCREASED →Transitioned To · AGIO MARGIN_INCREASED →Transitioned To · AGIO PROFITABILITY_INCREASED →Transitioned To · AGIO R_AND_D_INTENSITY_DECREASED →Transitioned To · AGIO SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.